The effects of RBBP6 knockdown on CDDP sensitivity in HeLa cervical cancer cells were evaluated by measuring the mRNA expression levels of wild-type p53 and Bcl-2 post-cisplatin treatment. The gene discussed is TP53; the disease is cervical carcinoma.